Vacuna against Zika virus
A single-dose mRNA-based vaccine shows positive results in experimental pharmacology against zika, according to research published today in the journal Nature. We observed a rapid and lasting protective immunity without adverse events. We think this vaccine candidate is a promising strategy in the fight against the Zika virus, said Drew Weissman, lead author of the study.
Temperatures could accelerate the success of a Zika vaccine
As warmer temperatures herald annoying mosquitoes, the researchers are feverishly working on several promising vaccines against zika, a virus known to infect humans through the bite of this insect. The speed and debilitating effects of last year's zika outbreak in the Western Hemisphere generated a race to develop a vaccine. Just over a year after this pandemic was declared a global health emergency, a group of volunteers are undergoing preliminary testing.
There is no specific medicine or vaccine for Zika virus. Treat the symptoms. Get plenty of rest. Drink fluids to prevent dehydration.Take medicine such as acetaminophen or paracetamol to reduce fever and pain.
Vaccine against zika is successful in mice
The successful results of the first tests of the vaccine can be tested this year in humans. A zika vaccine developed by researchers in Brazil and the United States was effective in tests with laboratory mice and could be tested this year in humans, Brazilian authorities said. The successful results of the first tests of the vaccine developed jointly by researchers from the University of Texas, the National Institute of Health of the United States and the Brazilian state center for health studies Institute Evandro Chagas, were highlighted Monday in a published article In the journal Nature Medicine.
Starts human trial of zika vaccine
Sinergium Biotech has been investigating a safe immunization against zika virus. It is expected that this year will begin tests in humans, after obtaining good results in mice in the preclinical stage. The zika virus expands throughout the region, and in the summer the countries seek to limit the circulation of the disease, transmitted by the same mosquito as dengue.
New Year update about Zika virus
The Zika virus (ZIKV) is a mosquito-borne virus originally discovered in the Zika Forest area in Uganda in 1947. It was not considered a relevant pathogen for humans until the outbreaks of fever illness that occurred in the Pacific area in 2007, and later in 2013-14. However, it was its arrival and dramatic spread in Brazil and other Latin American and Caribbean countries that alarmed public health authorities and the scientific community.
Zika and Guillain-Barré Syndrome: Guillain-Barré syndrome (GBS) is an uncommon sickness of the nervous system in which a person’s own immune system damages the nerve cells, causing muscle weakness, and sometimes, paralysis.
Treatment of zika virus almost found
Several scientists in the world have devoted their knowledge and efforts to obtain a medicine or vaccine that can be used in people infected with the zika virus, transmitted by the Aedes aegypti mosquito, which also transmits dengue and chikungunya. The search for a chemical formula triggered laboratory alarms since the World Health Organization (WHO) issued, in early December 2015, an epidemiological alert against zika virus due to its relationship with the increase of newborns with Microcephaly. Since then, many scientific studies have been undertaken worldwide.
Zika virus Overview
Zika virus disease is caused by the Zika virus, which is spread to people primarily through the bite of an infected mosquito (Aedes aegypti
and Aedes albopictus
). The illness is usually mild with symptoms lasting up to a week, and many people do not have symptoms or will have only mild symptoms.
New vaccine for Zika that is both effective and safe
Penn researchers have developed a first-of-its-kind vaccine to fight the Zika virus that demonstrates both safety and effectiveness. Participants in a clinical trial who received three doses of the GLS-5700 vaccine developed Zika-specific antibodies with minimal negative effects. These results open the door to future clinical trials and possible government approval for the vaccine. The study, which was published earlier this month in the New England Journal of Medicine, was a joint project of the Perelman School of Medicine, the Wistar Institute, Inovio Pharmaceuticals and GeneOne Life Science, Inc.